Is Absci (ABSI) Undervalued Following Hair Loss Trial Buzz?
Recent coverage of Absci (ABSI) has focused on its work on new therapies for pattern hair loss, an indication that has seen limited change since the 1990s and is now drawing early investor attention.
Absci’s share price has been volatile around the hair loss trial headlines, with the stock down 7.54% over the last day but showing a 37.17% 90 day share price return and a very large 1 year total shareholder return, which some investors may now be reassessing.
Scan other early stage biotech ideas that may be moving on clinical trial momentum by reviewing our hand picked list of 39 healthcare AI stocks.
Absci has already risen significantly over the past year, and the recent hair loss headlines have added further momentum to that move. The key question now is whether most of the upside is already reflected in the share price, which ultimately comes down to valuation.
Most Popular Narrative: 36.8% Undervalued
At a last close of $8.71 versus a narrative fair value of about $13.78, Absci is framed as materially undervalued, with that gap anchored in ambitious growth and profitability assumptions.
Advancement of ABS-201 toward two proof of concept readouts in androgenetic alopecia and endometriosis over the next 24 months positions Absci to convert large underpenetrated markets into meaningful revenue growth and improved earnings power.
Read the complete narrative. Read the complete narrative.
Want to see what is behind that valuation gap? The narrative leans on rapid revenue expansion, a sharp swing in margins and a rich future earnings multiple. Curious which specific milestones and financial assumptions are doing the heavy lifting in that model.
Result: Fair Value of $13.78 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Absci still faces real clinical and financing risk, with ABS-201 trial outcomes and future capital needs both capable of quickly challenging today’s upbeat narrative.
Find out about the key risks to this Absci narrative.
Next Steps
Given the mix of optimism and caution around Absci, it makes sense to review the underlying data in the near term and decide where you stand. Start by weighing the 1 key reward and 3 important warning signs
Looking for more investment ideas beyond Absci?
If Absci has caught your attention, do not stop there. Use the Simply Wall Street Screener to spot other opportunities that may fit your approach.
- Target potential mispricings by scanning a focused set of 45 high quality undervalued stocks that match strong fundamentals with appealing valuations.
- Strengthen your income approach by reviewing a curated group of 12 dividend fortresses that may help anchor long term returns with regular payouts.
- Protect your downside by filtering for 75 resilient stocks with low risk scores that pair sturdier balance sheets with more measured risk profiles.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com